當(dāng)前位置：首頁(yè) JCRQ2 期刊介紹(非官網(wǎng))

Rheumatology InternationalSCIE

國(guó)際簡(jiǎn)稱：RHEUMATOL INT 參考譯名：國(guó)際風(fēng)濕病學(xué)

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q2

基本信息：: ISSN：0172-8172; E-ISSN：1437-160X; 是否OA：未開(kāi)放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：GERMANY; 出版商：Springer Berlin Heidelberg; 出版語(yǔ)言：English; 出版周期：Tri-annual; 出版年份：1981; 研究方向：醫(yī)學(xué)-風(fēng)濕病學(xué)

評(píng)價(jià)信息：: 影響因子：3.2; H-index：66; CiteScore指數(shù)：7.3; SJR指數(shù)：0.971; SNIP指數(shù)：1.102

發(fā)文數(shù)據(jù)：: Gold OA文章占比：30.03%; 研究類文章占比：70.56%; 年發(fā)文量：231; 自引率：0.05; 開(kāi)源占比：0.2152; 出版撤稿占比：0; 出版國(guó)人文章占比：0.02; OA被引用占比：0.1906...

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Rheumatology International期刊介紹

RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.

RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.

Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.

期刊簡(jiǎn)介Rheumatology International期刊介紹

《Rheumatology International》自1981出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約16.月
醫(yī)學(xué)
RHEUMATOLOGY
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Rheumatology International Cite Score數(shù)據(jù)

CiteScore：7.3
SJR：0.971
SNIP：1.102

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Rheumatology	Q1	14 / 73	81%
大類：Medicine 小類：Immunology and Allergy	Q2	77 / 233	67%
大類：Medicine 小類：Immunology	Q2	92 / 236	61%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Rheumatology International 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	RHEUMATOLOGY 風(fēng)濕病學(xué)	4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書(shū)管理及圖書(shū)情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Rheumatology International JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：RHEUMATOLOGY	SCIE	Q2	19 / 57	67.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：RHEUMATOLOGY	SCIE	Q2	16 / 57	72.81%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門(mén)類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
Turkey145
Italy84
England74
USA74
Spain65
India53
GERMANY (FED REP GER)42
Japan41
South Korea38
Greece37

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Rheumatoid meningitis without a history of rheumatoid arthritis: a case report and literature review
Author: Huang, Gang; Wu, Lingfeng; Mei, Zhujun; Yao, Dongyuan

Journal: RHEUMATOLOGY INTERNATIONAL. 2023; Vol. 43, Issue 6, pp. 1173-1182. DOI: 10.1007/s00296-022-05209-x
2、Management of chronic rheumatic diseases in women 18-45 years of age in Asia Pacific: insights from patient and clinician surveys
Author: Tanaka, Yoshiya; Barrett, Claire; Hirano, Yuji; Ikeda, Kei; Paizis, Kathy; Sameshima, Azusa; Mountian, Irina; Wong, Priscilla C.

Journal: RHEUMATOLOGY INTERNATIONAL. 2023; Vol. 43, Issue 4, pp. 721-733. DOI: 10.1007/s00296-022-05206-0
3、Impact of cigarette smoking on rheumatoid arthritis-associated lung diseases: a retrospective case control study on clinical and radiological features and prognosis
Author: Ren, Jiaqi; Ding, Yanling; Zhao, Jinxia; Sun, Yongchang

Journal: RHEUMATOLOGY INTERNATIONAL. 2023; Vol. 43, Issue 2, pp. 293-301. DOI: 10.1007/s00296-022-05219-9
4、Bibliometric and altmetric analyses of publication activity in the field of idiopathic inflammatory myopathy in 2011-2021 based on web of science core collection databases
Author: Li, Mengxiang; Yin, Feng; He, Youxian; Zhang, Xue; Yu, Hao; Yang, Qiuyu; Xie, Xintong; Wei, Guangliang; Chen, Huidong; He, Chengsong; He, Yue; Chen, Jie

Journal: RHEUMATOLOGY INTERNATIONAL. 2023; Vol. 43, Issue 6, pp. 1121-1133. DOI: 10.1007/s00296-022-05211-3
5、Post-traumatic growth in adult patients with systemic lupus erythematosus: a cross-sectional study in China
Author: Xu, Rong; Yan, Qianqian; Xu, Zuocheng; Long, Xianming; Yin, Rulan

Journal: RHEUMATOLOGY INTERNATIONAL. 2023; Vol. 43, Issue 6, pp. 1077-1085. DOI: 10.1007/s00296-022-05233-x
6、IgG4-related disease with kidney and lymph nodes involvement: a case-based review
Author: Li, Ping; Zhou, Yuejia; Liu, Huanyu; Yin, Weihua; Li, Jian; Luo, Minghua

Journal: RHEUMATOLOGY INTERNATIONAL. 2023; Vol. 43, Issue 6, pp. 1183-1193. DOI: 10.1007/s00296-023-05295-5
7、High serum hepcidin is associated with the occurrence of anemia in anti-myeloperoxidase antibody-associated vasculitis with normal kidney function: a cross-sectional study
Author: Tong Chen, Peng-Cheng Xu, Shui-Yi Hu, Shan Gao, Jun-Ya Jia, Tie-Kun Yan

Journal: RHEUMATOLOGY INTERNATIONAL, 2019, Vol., , DOI:10.1007/s00296-019-04292-x
8、Systemic vasculitis involving the breast: a case report and literature review
Author: Jiaqi Ren, Jianying Liu, Jing Su, Jingfeng Zhang, Jinxia Zhao

Journal: RHEUMATOLOGY INTERNATIONAL, 2019, Vol., , DOI:10.1007/s00296-019-04279-8